Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 100
Filter
Add more filters











Publication year range
1.
Adv Mater ; 36(36): e2403549, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38723270

ABSTRACT

It is a pressing need to develop new energy materials to address the existing energy crisis. However, screening optimal targets out of thousands of material candidates remains a great challenge. Herein, an alternative concept for highly effective materials screening based on dual-atom salphen catalysis units, is proposed and validated. Such an approach simplifies the design of catalytic materials and reforms the trial-and-error experimental model into a building-blocks-assembly like process. First, density functional theory (DFT) calculations are performed on a series of potential catalysis units that are possible to synthesize. Then, machine learning (ML) is employed to define the structure-performance relationship and acquire chemical insights. Afterward, the projected catalysis units are integrated into covalent organic frameworks (COFs) to validate the concept Electrochemical tests confirming that Ni-SalphenCOF and Co-SalphenCOF are promising conductive agent-free oxygen evolution reaction (OER) catalysts. This work provides a fast-tracked strategy for the design and development of functional materials, which serves as a potentially workable framework for seamlessly integrating DFT calculations, ML, and experimental approaches.

2.
Cancers (Basel) ; 13(18)2021 Sep 18.
Article in English | MEDLINE | ID: mdl-34572904

ABSTRACT

T cell acute lymphoblastic leukemia (T-ALL) is one of the most common causes of death in pediatric malignancies. However, the clinical chemotherapy for T-ALL has been limited by numerous side effects, emphasizing that novel anti-T-ALL drugs are urgently needed. Herein, a series of 2-acyl-1-dimethylaminomethyl-ferrocenes for cancer therapy have been evaluated. Among them, F1 and F3 exhibited potent cytotoxicity against T-ALL cell lines, especially Jurkat cells, with low cytotoxicity for normal cells. Further mechanistic studies revealed that F1 and F3 could induce apoptosis in Jurkat cells by destructing mitochondrial membrane, enhancing reactive oxygen species (ROS) generation, decreasing the Bcl-2/Bax ratio, releasing Cytochrome c, and increasing the expression of Cleaved Caspase-9/-3 and Cleaved PARP. Additionally, F1 and F3 could suppress cell proliferation and arrest the cell cycle at G0/G1 phase through the PI3K/Akt/mTOR signaling pathway by down-regulating the expression of CDK6, Cyclin D1, p-Akt, p-GSK-3ß, p-mTOR, p-p70 S6K, and up-regulating the expression of P21 and P27, which would also be a possible mechanism. Consequently, ferrocene derivatives F1 and F3 could induce apoptosis through a mitochondria-dependent pathway mediated by ROS, and cell cycle arrest at G0/G1 phase via the PI3K/Akt/mTOR signaling pathway in Jurkat cells. The present study provided fundamental insights into the clinical application of F1 and F3 for the treatment of T-ALL.

3.
Mar Drugs ; 19(4)2021 Mar 30.
Article in English | MEDLINE | ID: mdl-33808126

ABSTRACT

Hepatitis B virus (HBV) infection remains a major global health problem. It is therefore imperative to develop drugs for anti-hepatitis B with high-efficiency and low toxicity. Attracted by the observations and evidence that the symptoms of some patients from the Southern Fujian, China, suffering from hepatitis B were alleviated after daily eating an edible marine mollusk, Thais clavigera (Küster 1860) (TCK). Water-soluble polysaccharide from TCK (TCKP1) was isolated and characterized. The anti-HBV activity of TCKP1 and its regulatory pathway were investigated on both HepG2.2.15 cell line and HBV transgenic mice. The data obtained from in vitro studies showed that TCKP1 significantly enhanced the production of IFN-α, and reduced the level of HBV antigens and HBV DNA in the supernatants of HepG2.2.15 cells in a dose-dependent manner with low cytotoxicity. The result of the study on the HBV transgenic mice further revealed that TCKP1 significantly decreased the level of transaminases, HBsAg, HBeAg, and HBV DNA in the serum, as well as HBsAg, HBeAg, HBV DNA, and HBV RNA in the liver of HBV transgenic (HBV-Tg) mice. Furthermore, TCKP1 exhibited equivalent inhibitory effect with the positive control tenofovir alafenamide (TAF) on the markers above except for HBV DNA even in low dosage in a mouse model. However, the TCKP1 high-dose group displayed stronger inhibition of transaminases and liver HBsAg, HBeAg, and HBV RNA when compared with those of TAF. Meanwhile, inflammation of the liver was, by pathological observation, relieved in a dose-dependent manner after being treated with TCKP1. In addition, elevated levels of interleukin-12 (IL-12) and interferon γ (IFN-γ), and reduced level of interleukin-4 (IL-4) in the serum were observed, indicating that the anti-HBV effect of TCKP1 was achieved by potentiating immunocyte function and regulating the balance of Th1/Th2 cytokines.


Subject(s)
Antiviral Agents/pharmacology , Hepatitis B virus/drug effects , Hepatitis B/drug therapy , Mollusca/metabolism , Polysaccharides/pharmacology , Animals , Antiviral Agents/isolation & purification , Cytokines/metabolism , Disease Models, Animal , Hep G2 Cells , Hepatitis B/immunology , Hepatitis B/metabolism , Hepatitis B/virology , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Host-Pathogen Interactions , Humans , Inflammation Mediators/metabolism , Mice, Transgenic , Polysaccharides/isolation & purification , Th1-Th2 Balance/drug effects , Viral Load
4.
Int J Mol Sci ; 22(6)2021 Mar 18.
Article in English | MEDLINE | ID: mdl-33803555

ABSTRACT

In this study, detailed information on hepatocellular carcinoma (HCC) cells (HepG-2, SMMC-7721, and HuH-7) and normal human liver cell L02 treated by ferrocene derivatives (compounds 1, 2 and 3) is provided. The cell viability assay showed that compound 1 presented the most potent and selective anti-HCC activity. Further mechanism study indicated that the proliferation inhibition effect of compound 1 was associated with the cycle arrest at the G0/G1 phase and downregulation of cyclin D1/CDK4. Moreover, compound 1 could induce apoptosis in HCC cells by loss of mitochondrial membrane potential (ΔΨm), accumulation of reactive oxygen species (ROS), decrease in Bcl-2, increase in BAX and Bad, translocation of Cytochrome c, activation of Caspase-9, -3, and cleavage of PARP. These results indicated that compound 1 would be a promising candidate against HCC through G0/G1 cell cycle arrest-related proliferation inhibition and mitochondrial pathway-dependent apoptosis.


Subject(s)
Apoptosis/drug effects , Carcinoma, Hepatocellular/pathology , Ferrous Compounds/pharmacology , G1 Phase Cell Cycle Checkpoints/drug effects , Liver Neoplasms/pathology , Metallocenes/pharmacology , Mitochondria/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Cytochromes c/metabolism , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Models, Biological , Reactive Oxygen Species/metabolism , Resting Phase, Cell Cycle/drug effects
5.
Curr Gene Ther ; 21(1): 72-80, 2021.
Article in English | MEDLINE | ID: mdl-33183200

ABSTRACT

BACKGROUND: Lung cancer remains the most common cause of cancer-related deaths in China and worldwide. Traditional surgery and chemotherapy do not offer an effective cure, although gene therapy may be a promising future alternative. Kallistatin (Kal) is an endogenous inhibitor of angiogenesis and tumorigenesis. Recombinant adeno-associated virus (rAAV) is considered the most promising vector for gene therapy of many diseases due to persistent and long-term transgenic expression. OBJECTIVE: The aim of this study was to investigate whether rAAV9-Kal inhibited NCI-H446 subcutaneous xenograft tumor growth in mice. METHODS: The subcutaneous xenograft mode was induced by subcutaneous injection of 2×107 H446 cells into the dorsal skin of BALB/c nude mice. The mice were administered with ssrAAV9-Kal (single- stranded rAAV9) or dsrAAV9-Kal (double-stranded rAAV9) by intraperitoneal injection (I.P.). Tumor microvessel density (MVD) was examined by anti-CD34 staining to evaluate tumor angiogenesis. RESULTS: Compared with the PBS (blank control) group, tumor growth in the high-dose ssrAAV9-Kal group was inhibited by 40% by day 49, and the MVD of tumor tissues was significantly decreased. CONCLUSION: The results indicate that this therapeutic strategy is a promising approach for clinical cancer therapy and implicate rAAV9-Kal as a candidate for gene therapy of lung cancer.


Subject(s)
Genetic Therapy/methods , Genetic Vectors/metabolism , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Serpins/metabolism , Serpins/therapeutic use , Animals , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/metabolism , Cell Line, Tumor , Dependovirus/genetics , HEK293 Cells , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Serpins/genetics , Xenograft Model Antitumor Assays
6.
PLoS Pathog ; 16(7): e1008664, 2020 07.
Article in English | MEDLINE | ID: mdl-32678826

ABSTRACT

Establishing latent infection but retaining the capability to reactivate in certain circumstance is an ingenious tactic for retroviruses to persist in vivo while evading host immune surveillance. Many evidences indicate that Human T-cell leukemia virus type 1 (HTLV-1) is not completely silent in vivo. However, signals that trigger HTLV-1 latency-reactivation switching remain poorly understood. Here, we show that aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, plays a critical role in HTLV-1 plus-strand expression. Importantly, HTLV-1 reactivation could be tunably manipulated by modulating the level of AHR ligands. Mechanistically, activated AHR binds to HTLV-1 LTR dioxin response element (DRE) site (CACGCATAT) and drives plus-strand transcription. On the other hand, persistent activation of nuclear factor kappa B (NF-κB) pathway constitutes one key prerequisite for AHR overexpression in HTLV-1 infected T-cells, setting the stage for the advent of AHR signaling. Our findings suggest that HTLV-1 might achieve its reactivation in vivo when encountering environmental, dietary, microbial and metabolic cues that induce sufficient AHR signaling.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/metabolism , HTLV-I Infections/virology , Human T-lymphotropic virus 1/metabolism , Receptors, Aryl Hydrocarbon/metabolism , Virus Activation/physiology , Virus Latency/physiology , Cell Line , HTLV-I Infections/metabolism , Humans , T-Lymphocytes/virology
7.
Mar Drugs ; 18(3)2020 Mar 12.
Article in English | MEDLINE | ID: mdl-32178323

ABSTRACT

The aims of this study were to investigate the antioxidant, hypolipidemic and hepatic protective effects of Phascolosoma esculenta polysaccharides (PEP). PEP was prepared from Phascolosoma esculenta by enzyme hydrolysis and its characterization was analyzed. The antioxidant activities of PEP were evaluated by the assays of scavenging 1,1-Diphenyl-2-picrylhydrazyl (DPPH), superoxide anion, hydroxyl radicals and chelating ferrous ion in vitro. It showed that PEP could scavenge radicals effectively and had favorable antioxidant activities. In the meantime, the hypolipidemic effect of PEP was investigated in vivo by using mice model fed with high-fat diet with or without PEP treatment. Compared with the hyperlipidemic mice without treatment, the serum levels of total cholesterol (TC) (30.1-35.7%, p < 0.01), triglyceride (TG) (24.5-50.8%, p < 0.01 or p < 0.05), low-density lipoprotein cholesterol (LDL-C) (49.6-56.8%, p < 0.01) and liver levels of TC (21.0-28.4%, p < 0.01), TG (23.8-37.0%, p < 0.01) decreased significantly, whereas serum high-density lipoprotein cholesterol (HDL-C) (47.7-59.9%, p < 0.01 or p < 0.05) increased significantly after treatment with different dosage of PEP (0.2, 0.4 and 0.8 g per kg body weight, respectively). In addition, superoxide dismutase (SOD) (10.2-22.2% and 18.8-26.9%, p < 0.05), glutathione peroxidase (GSH-Px) (11.9-15.4% and 26.6-30.4%, p < 0.05) activities in serum and liver enhanced markedly while aspartate aminotransferase (AST) (18.7-29.6% and 42.4-58.0%, p < 0.05), alanine transaminase (ALT) (42.7-46.0% and 31.2-42.2%, p < 0.05) activities, as well as the levels of malondialdehyde (MDA) (15.9-24.4% and 15.0-16.8%, p < 0.01 or p < 0.05) in serum and liver reduced markedly. Moreover, the histopathological observation of livers indicated that PEP could attenuate liver cell injury. The animal experimental results demonstrated that PEP exerted hypolipidemic and hepatoprotective roles in hyperlipidemic mice. In summary, our results above suggest that PEP might be a potential natural antioxidant and utilized as a therapeutic candidate for hyperlipidemia.


Subject(s)
Antioxidants/pharmacology , Chemical and Drug Induced Liver Injury/prevention & control , Hypolipidemic Agents/pharmacology , Polysaccharides/pharmacology , Protective Agents/pharmacology , Animals , Body Weight/drug effects , Diet, High-Fat , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , Iron Chelating Agents/pharmacology , Lipids/blood , Male , Mice , Polysaccharides/chemistry , Polysaccharides/therapeutic use
8.
Front Biosci (Landmark Ed) ; 25(6): 1184-1201, 2020 03 01.
Article in English | MEDLINE | ID: mdl-32114429

ABSTRACT

N6-methyladenosine (m6A) modification, which alters gene expression, is the most prevalent internal modification of eukaryotic mRNA. m6A modification is dynamic and reversible that is regulated by three associated protein groups: methyltransferases or writers, demethylases or erasers, and m6A-binding proteins or readers. m6A modification is involved in all phases of RNA life, from RNA folding and structure, stability, splicing, nuclear export, translational modulation to RNA degradation. Recent findings show that the abnormal level of m6A modification causes aberrant expression of important viral genes. Here, we reviewe m6A role in gene expression and its contribution to the development  of human viral diseases. Particularly, we would focus on viruses associated with human diseases including HIV-1, IAV, HBV, HCV, EBV and so on to find a novel approach and provide a new sight for the innovative treatment of human viral diseases.


Subject(s)
Adenosine/analogs & derivatives , RNA, Viral/genetics , Virus Diseases/genetics , Viruses/genetics , Adenosine/metabolism , Humans , Methylation , Methyltransferases/genetics , Methyltransferases/metabolism , RNA Folding , RNA Stability , RNA, Viral/chemistry , RNA, Viral/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Virus Diseases/metabolism , Virus Diseases/virology , Viruses/metabolism
9.
Molecules ; 24(24)2019 Dec 12.
Article in English | MEDLINE | ID: mdl-31842361

ABSTRACT

Schefflera heptaphylla (L.) Frodin, are commonly used in anti-inflammatory, analgesic, traumatic bleeding and hemostasisas. In this paper, the coagulation effect of the ethanol extract (Set), ethyl acetate phase (Sea) and n-butanol phase (Sbu) was evaluated by prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen content (FIB) assays in vitro. Then, Three main lupanine triterpenes (compounds A-C) were isolated and identified from Sea and Sbu by a bioassay-guided method and their structure were identified as 3α-Hydroxy-lup-20(29)-ene-23, 28-dioic acid, betulinic acid 3-O-sulfate and 3α-Hydroxy-lup-20(29)-ene-23, 28-dioic acid 28-O-(α-l-rhamnopyranosyl(1→4)-O-ß-d-glucopyranosyl(1→6))-ß-d-glucopyranoside) by spectroscopic data analysis. Among of them, compound B was confirmed to have significant coagulant effect in vitro. Furthermore, the pro-coagulation mechanism of S. heptaphylla extracts and compound B were investigated by measuring whole blood viscosity (WBV), plasma viscosity (PV), erythrocyte sedimentetion rate (ESR), pack cell volume (PCV), APTT, PT, TT, and FIB in vivo. Meanwhile, the levels of thromboxane B2 (TXB2), 6-keto prostaglandin F1α (6-keto-PGF1α), endothelial nitric oxide synthase (eNOS) and (endothelin-1) ET-1 were detected. The bleeding time (BT) was tested by tail bleeding method, which proved the traumatic bleeding and hemostasis activities of S. heptaphylla. The pharmacology experiments showed that the Set, Sea, Sbu and compound B has significant pro-coagulation effect. In addition, compound B might be the main constituent of pro-coagulation in S. heptaphylla These results could support the fact that S. heptaphylla could be used traditionally to cure traumatic bleeding, and the pro-coagulation effects were associated with the regulation of vascular endothelium active substance and hemorheology parameters.


Subject(s)
Araliaceae/chemistry , Blood Coagulation/drug effects , Coagulants , Hemorrhage , Animals , Coagulants/chemistry , Coagulants/pharmacology , Endothelin-1/blood , Female , Hemorrhage/blood , Hemorrhage/drug therapy , Male , Nitric Oxide Synthase Type III/blood , Partial Thromboplastin Time , Prothrombin Time , Rats , Rats, Sprague-Dawley , Thromboxane B2/blood
10.
Virol J ; 16(1): 133, 2019 11 11.
Article in English | MEDLINE | ID: mdl-31711514

ABSTRACT

BACKGROUND: N6-methyladenosine (m6A) modification is the most prevalent internal modification of eukaryotic mRNA modulating gene expression. m6A modification is a dynamic reversible process regulated by three protein groups: methyltransferases (writers), demethylases (erasers), and m6A-binding proteins (readers). m6A modification is involved in all phases of RNA metabolism, including RNA folding, stability, splicing, nuclear exporting, translational modulation and degradation. MAIN BODY: In recent years, numerous studies have reported that abnormal m6A modification causes aberrant expression of important viral genes. Herein, we review the role of m6A in viral lifecycle and its contribution to the pathogenesis of human diseases. Particularly, we focus on the viruses associated with human diseases such as HIV-1, IAV, HBV, HCV, EBV and many others. CONCLUSIONS: A better understanding of m6A-virus relationship would provide new insights into the viral replication process and pathogenesis of human diseases caused by viruses. In addition, exploration of the role of m6A in disease-causing viruses will reveal novel approaches for the treatment of such diseases.


Subject(s)
Adenosine/analogs & derivatives , Virus Diseases/virology , Virus Physiological Phenomena , Adenosine/metabolism , Animals , Gene Expression Regulation, Viral , Humans , RNA Processing, Post-Transcriptional , RNA, Viral/metabolism , Virus Replication , Viruses/genetics
SELECTION OF CITATIONS
SEARCH DETAIL